Canada: Food and Drugs Law

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
Distilled Law, Part 1: Whisky Business: Alberta's New Spirit Standards And The Future Of AI Use In Legislative Drafting
The Government of Alberta has reportedly become the first jurisdiction in Canada to use artificial intelligence (“AI”) in the initial drafting of the Alberta Whisky Act (the “Whisky Act”). The Whisky Act, which came into effect on May 21, 2026, establishes new standards and definitions for what qualifies as “Alberta Whisky”, including requirements relating to production standards, ingredients, and processes. According to the province, AI was used as part of the drafting process, with government officials and legislative counsel retaining responsibility for review, revision, and all levels of approval.
Canada Healthcare
F
Fasken
Article
Canada Considers Positive List Approach For Food Contact Substances
Health Canada has launched a public consultation on a proposed regulatory overhaul that would fundamentally transform how food packaging materials are evaluated and approved for use in Canada. The agency is considering implementing a mandatory notification system and potentially creating a binding positive list of approved substances, marking a significant departure from the current voluntary Letter of No Objection framework.
Canada Consumer
S
Steptoe LLP
Article
Santé Canada Lance Un Portail De Recherche Des Essais Cliniques Et Des Lignes Directrices Sur L’enregistrement Et La Divulgation Des Résultats
Le 29 juillet 2026, Santé Canada a lancé un nouveau portail de recherche pour les essais cliniques et publié sa ligne directrice sur l’enregistrement des essais cliniques et la divulgation publique des résultats afin de donner au public un meilleur accès aux renseignements sur les essais cliniques autorisés au Canada.
Canada Healthcare
FF
Fasken (French)
Article
Health Canada Obtains Permanent Injunction To Prevent Illegal Sale Of Injectable Peptides By Canlab Research
Health Canada has secured a permanent injunction against Canlab Research, a Quebec-based online retailer, preventing the company from manufacturing, distributing, or selling unauthorized injectable peptides in Canada. This enforcement action follows years of regulatory warnings and provisional court orders aimed at stopping the illegal sale of peptide drugs promoted with unproven health claims for anti-aging, weight loss, and athletic performance.
Canada Healthcare
SB
Smart & Biggar
Article
Health Canada Launches New Clinical Trial Search Portal And Publishes Updated Guidance
Health Canada has launched a new Clinical Trial Search Portal and released updated guidance on clinical trial registration and public disclosure of results. The portal provides searchable information on Health Canada-authorized clinical trials for pharmaceutical, biologic and radiopharmaceutical drugs, while the guidance outlines expectations for sponsors regarding trial registration and summary result reporting.
Canada Healthcare
SB
Smart & Biggar
Article
Entering The Canadian Market: Key Regulatory And Compliance Considerations For Whisky And Spirits
Canada's whisky and spirits market presents significant opportunities for international producers, but success requires careful navigation of a dual regulatory framework. Federal laws govern production standards, excise duties, and labelling requirements, while each province maintains its own liquor authority controlling distribution, sales, marketing, and pricing within its borders. Understanding these overlapping jurisdictions and tailoring market entry strategies to provincial variations is essential for
Canada Consumer
AB
Aird & Berlis LLP
Article
Pharmaceutical And Life Sciences Sector Federal Task Force Releases Final Report
On July 24, 2026, Health Canada published the Final Report of the Pharmaceutical and Life Sciences Sector Task Force to the Ministers of Health and Industry. The Task Force was launched in March 2026 as a joint federal initiative of Health Canada and Innovation, Science and Economic Development Canada. The Task Force’s mandate was to support reliable and sustainable access to pharmaceutical products in Canada and identify made-in-Canada solutions that drive innovation, competitiveness and long-term growth in the life sciences sector.
Canada Healthcare
F
Fasken
Article
Santé Canada Renforce Le Cadre De Gestion Des Pénuries De Médicaments Et D’instruments Médicaux
Le 17 juin 2026, Santé Canada a publié le Règlement modifiant certains règlements pris en vertu de la Loi sur les aliments et drogues (pénuries et cessation de la vente de drogues et d’instruments médicaux) (le « Règlement modificatif »), qui apporte des modifications au Règlement sur les aliments et drogues (RAD) et au Règlement sur les instruments médicaux (RIM).
Canada Healthcare
FF
Fasken (French)
Article
Pharmaceutical And Life Sciences Sector Task Force Submits Final Report To The Ministers Of Health And Industry
The Pharmaceutical and Life Sciences Sector Task Force has released its final report addressing Canada's challenges in medication access, regulatory processes, and life sciences competitiveness. The report examines structural issues including lengthy reimbursement pathways, underperforming clinical trial environments, and erosion of domestic investment, while proposing 39 recommendation areas to strengthen Canada's health sovereignty and industrial strategy.
Canada Healthcare
SB
Smart & Biggar
Article
When Claims Travel Faster Than Facts: Substantiating Functional Food Claims In Canada
As functional food health claims spread faster than scientific validation can keep pace, Canadian food companies face mounting regulatory and reputational risks. This analysis examines how Canada's food regulatory framework attempts to balance consumer protection with market innovation, while exploring whether current approval pathways can match the accelerating demands of the functional foods marketplace.
Canada Consumer
GW
Gowling WLG
Article
Teva And Samsung Bioepis Enter Into Commercialization Agreement For OPUVIZ In Canada
Teva Pharmaceutical Industries and Samsung Bioepis have announced a strategic partnership to commercialize OPUVIZ, a biosimilar referencing EYLEA, in the Canadian market. The agreement divides responsibilities between Samsung Bioepis handling product registration and manufacturing while Teva Canada leads commercialization efforts. OPUVIZ has already received Health Canada approval for treating multiple eye conditions including wet age-related macular degeneration and diabetic macular edema.
Canada Healthcare
GP
Goodwin Procter LLP
Article
The More Things Change, The More They Stay The Same: The Supreme Court Determines The Patentability Of Methods Of Medical Treatment
The Supreme Court of Canada has issued its most significant ruling on medical treatment patents in over fifty years, addressing whether dosing-regimen claims for schizophrenia medication constitute unpatentable methods of medical treatment. The 7-2 decision establishes a new framework for evaluating pharmaceutical patents, focusing on whether implementing the claimed invention requires professional medical skill and judgment. This landmark case provides crucial guidance for life sciences companies seeking p
Canada IP
C
Cassels
See more